Flüge T, Fabel H, Wagner T O, Schneider B, Forssmann W G
Department of Respiratory Medicine, Hannover Medical School, Germany.
Regul Pept. 1995 Nov 10;59(3):357-70. doi: 10.1016/0167-0115(95)00106-l.
In animal studies, the bronchial effects of urodilatin (URO, CDD/ANP-95-126, INN: ularitide) were superior to those of cardiodilatin/atrial natriuretic peptide (CDD, CDD/ANP-99-126). We compared the bronchodilating properties of intravenous URO and CDD in 36 clinically stable asthmatics showing a beta 2-agonist-induced increase of the FEV1 by > or = 15%. Any aerosol medication was discontinued for at least 8 h prior to the study. After baseline measurements of lung function parameters (FEV1, VC, PEF, MEF75, MEF50, MEF25) an intravenous infusion of 5.7, 11.4 or 17.1 pmol/kg/min URO or CDD was administered for 40 min in the morning. All measurements were repeated every 10 min during the infusion, for 30 min thereafter, and after the inhalation of 1.25 mg salbutamol (SALB). Both peptides had significant effects. While 11.4 pmol/kg/min URO dilated the central airways (FEV1, PEF, MEF75) slightly more potently than the peripheral bronchioles (MEF50, MEF25), 17.1 pmol/kg/min URO was as effective as SALB at all levels of the tracheobronchial tree. CDD reached only 50% of the SALB effect without a predominant localization of its action. The cardiovascular parameters revealed a significantly stronger vasorelaxant activity of CDD. In conclusion, the dose-dependent bronchodilating properties of intravenous URO were significantly superior to those of CDD.
在动物研究中，尿舒张素（URO，CDD/ANP - 95 - 126，国际非专利名称：ularitide）对支气管的作用优于心钠素/心房利钠肽（CDD，CDD/ANP - 99 - 126）。我们比较了静脉注射URO和CDD对36例临床稳定哮喘患者的支气管扩张特性，这些患者使用β2激动剂后FEV1增加≥15%。在研究前至少8小时停用任何气雾剂药物。在对肺功能参数（FEV1、VC、PEF、MEF75、MEF50、MEF25）进行基线测量后，于上午静脉输注5.7、11.4或17.1 pmol/kg/min的URO或CDD，持续40分钟。在输注期间每10分钟重复所有测量，此后30分钟内每10分钟重复测量一次，在吸入1.25毫克沙丁胺醇（SALB）后再次测量。两种肽均有显著作用。虽然11.4 pmol/kg/min的URO对中央气道（FEV1、PEF、MEF75）的扩张作用略强于外周细支气管（MEF50、MEF25），但17.1 pmol/kg/min的URO在气管支气管树的所有水平上与SALB效果相同。CDD仅达到SALB效果的50%，且其作用无主要定位。心血管参数显示CDD的血管舒张活性明显更强。总之，静脉注射URO的剂量依赖性支气管扩张特性明显优于CDD。
